Clinical Prevalence and Risk Stratification Post-market surveillance and patient reports indicate hair loss occurs in approximately 515% of tirzepatide users, though exact prevalence varies by study design and follow-up duration
These symptoms are most intense during dose escalation, particularly in the first 4-8 weeks of treatment, and they all share one critical consequence
Ive noticed major improvements in swelling, discomfort, and overall healing, and I truly believe my results and recovery experience would not be the same without their help
For people using tirzepatide for type 2 diabetes management, subtherapeutic doses mean inadequate blood sugar control
However, if accompanied by symptoms such as extreme fatigue, hair loss, or unexplained weight gain, contact your GP to exclude thyroid dysfunction or other underlying conditions
FAQs Is tirzepatide more effective than semaglutide